Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Adv Mater. 2016 Oct 31;29(1):10.1002/adma.201603276. doi: 10.1002/adma.201603276

Figure 1.

Figure 1

(a) Schematic representation of the PEGylated BP theranostic delivery platform. 1: PEG-NH2 (surface modification), 2: DOX (therapeutic agents), 3: Cy7-NH2 (NIR imaging agents), 4: FA-PEG-NH2 (Targeting agents), 5: FITC-PEG-NH2 (fluorescent imaging agents). (b) Screening and summary of the endocytosis pathways and biological activities of PEGylated BP NSs in cancer cells.